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Experimental and Clinical Evaluation of Nootropic 
Activity of Bacopa monniera Linn. (Brahmi)
Bacopa monniera Linn. (Brahmi) is an annual creeper belonging to family 
Scrophulariaceae and growing all over the Indian sub-continent in marshy areas. It is a 
major Medhya Rasayana used in Ayurveda for treatment of memory disorders. Large 
number of saponins and glycosides has been isolated from the plant. Most of the 
experimental and clinical studies have been done with crude extracts or standardized 
preparation of the two active saponins Bacosides A and B.
Extracts or saponin mixture facilitate learning, improve consolidation of learned 
behavior and delay extinction in several models of learnt behavior in normal rats and 
mice as well as in chemically induced or transgenic models of Alzheimer's disease. 
They also prevent or reverse amnesia produced by drugs, stress or ischemic hypoxia. 
Other CNS effects include anti-anxiety, anti-convulsant and analgesic activity. Several 
mechanisms have been proposed to explain the mechanism of these CNS effects.
Extracts as well as the bacoside preparation have been found safe and well tolerated in 
healthy volunteers in single dose or chronic administration for several weeks in a 
number of double blind placebo controlled studies in India and abroad. Chronic 
administration signiﬁcantly improved information processing, learning and memory 
consolidation. It was found more effective than caffeine in a comparative study.
Double blind placebo controlled studies with bacoside preparation have demonstrated 
beneﬁcial effects and safety in elderly patients with Age Related Memory Impairment 
and in children with Attention Deﬁcit Memory Disorder. It has also been found useful 
in anxiety neurosis, epilepsy and sleep disturbances in post menopausal women. 
The standardized preparation is marketed as a prescription drug after having obtained 
the necessary regulatory approval in India, Australia, New Zealand and South Africa 
and as an OTC product in several other south east Asian and African countries.    
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Introduction
 Bacopa monniera Linn. (Syn. 
Herpestis monniera Linn H.B. & K, 
Brahmi) is an annual creeper belonging to 
family Scrophulariaceae and found all 
over the Indian sub-continent in damp and 
marshy areas. It is an important plant in 
Ayurvedic materia medica. It is classiﬁed 
in Charak Samhita as a Medhya rasayana 
for  improvement of  memory and 
described in Sushruta Samhita as being 
efﬁcacious in loss of intellect and 
memory(1). It has been as a single herb 
and also in formulations with other 
i n g r e d i e n t s .  C e n t e l l a  a s i a t i c a 
(Hydrocotyle asiatica) is also used in 
Ayurveda for similar indications and thee 
is often confusion between these 2 plants. 
Singh and Sinha (2) have clariﬁed that 
Bacopa is Brahmi and Centella is 
mandookparni. They have also stated that 
the former is more potent and used as drug 
while the later is recommended as a 
dietary constituent (Saka dravya or 
vegetable).
 Chemical studies on the plant 
were initiated in 1931 by Bose and Bose 
(3) with isolation of the alkaloid Brahmine 
followed by isolation of a saponin, 
hersaponin by Sastri et al in 1969 (4). 
De ta i l ed  chemica l  ana lys i s  was 
undertaken at Central Drug Research 
Institute Lucknow (CDRI), leading to 
isolation of the major saponins, Bacosides 
A and  B  (5 -7 ) .  Bacos ide  A was 
subsequently shown to be a mixture of 4 
aglycones, Bacogenins A  (8-10). Other 
1-4
minor constituents isolated at CDRI were 
Bacoside A (11) and A (12). Several 
1 3 
minor constituents have been isolated 
subsequently by investigators elsewhere. 
These include: 4 dammarane type 
triterpinoid Bacosaponins A-D (13, 14);   
2  pseudo ju jubogen in  g lycos ides 
Bacoposides I and II (15) and saponins 
Bacopasides III-V (16) and Bacosaponin 
G (17). Most of the experimental studies 
have been done with crude extracts or 
standardized mixture of Bacosides A and 
B (Bacoside mixture) developed at CDRI
Experimental Studies
 Major emphasis in experimental 
studies has been on analyzing its effect on 
learning and memory but some other CNS 
effects have also been reported. The major 
ﬁndings have been summarized below 
under effects on learning and memory, 
anti-amnesic activity and other CNS 
effects.
Effects on Learning and Memory
 Prakash and Sirsi (18) published 
the ﬁrst report in 1962 on improvement of 
performance of rats in motor learning with 
alcoholic extract. Sinha (19) reported 
facilitation of acquisition, consolidation 
and retention with the glycoside, 
hersaponin, in a brightness discrimination 
test. Improvement in maze learning by 
rats with a decoction was observed by Dey 
et al (20).
 A more detailed study has been at 
CDRI, initially with the alcoholic extract 
in rats (21). Animals treated with 40 
mg/kg extract per oral for 3 or more days 
showed better acquisition, improved 
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retention and delayed extinction in a 
s h o c k  m o t i v a t e d  b r i g h t n e s s 
discrimination test. It also reduced 
reaction time signiﬁcantly in an active 
conditioned ﬂight test and improved 
performance in Sidman's continuous 
response test. Similar effect was obtained 
in the ﬁrst 2 tests with a much lower dose 
(2.5-7.5 mg/kg) of Bacoside mixture. It 
also signiﬁcantly reduced lithium chloride 
intake in conditioned taste aversion test 
(22). It abolished the 'Kamin's deﬁcit' (23) 
in the re-learning schedule of Y-maze test 
(24). Improvement in learning has been 
conﬁrmed in rat (25) and mouse (26, 27) 
from other laboratories.
 Bhattacharya et al (28) and 
Uabundit et al (29) have shown its 
beneﬁcial effect in a rat model of 
Alzheimer disease. Rastogi et al (30) have 
found that long term (3 months) treatment 
with bacosides prevented age-associated 
neuronal degeneration in female Wistar 
rats. Charles et al (31) have reported 
similar reversal of galactose induced 
attenuation of contextual associated 
learning in ageing rats. A reduction in β-
amyloid level in brain associated with 
improvement in Y-maze performance and 
open ﬁeld hyper-locomotion has been 
obtained in doubly transgenic PSAPP 
mice (32). Protection against β-amyloid 
induced cell death has been observed in 
primary cortical cell culture also (33). 
These results are suggestive of its 
potential utility in patients of Alzheimer's 
disease.
Anti-amnesic Activity   
 Bacosides reverse retrograde 
a m n e s i a  i n  r a t s  p r o d u c e d  b y 
immobilization stress, electroconvulsive 
shock or scopolamine (1).Reversal of 
scopolamine amnesia has also been 
reported by Manjarekar (34) and Das et al 
(35). Studies in mice have shown their 
ability to reverse amnesia induced by 
diazepam (36), NOS inhibitor L-NNA 
(37), phenytoin (38), 1-(m-chlorophenyl) 
biguanide (39) hypobaric hypoxia (40) 
and ischemia (41).
Other CNS Effects
 Extracts and pure compounds 
isolated from Bacopa have been shown to 
have tranquilizing (42), anti-anxiety (43-
45), anti-depressant (45-47), anti-
convulsant (48) and analgesic (49) 
activities. Antagonism of haloperidol 
induced catalepsy also has been reported 
(50).
Studies on Mechanism of Action 
 Bacosides enhanced protein 
k inase  ac t iv i ty  in  h ippocampus , 
hypothalamus and cerebral cortex (1). 
They also prevent decrease in SOD, intra-
neuronal lipofuschin accumulation and 
necrotic changes induced by aluminum 
t r i c h l o r a t e  i n  C A - 1  r e g i o n  o f 
hippocampus (51) and cerebral cortex 
(52). Bhattacharya et al (53) have reported 
anti-oxidant, free radical scavenging and 
anti-lipid peroxidation effect of Bacopa 
extract.  Rasso et al (54) have found 
protection against NOS inhibition 
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evidenced by altered NO synthesis, 
reduction in intracellular oxidants and 
prevention of DNA damage in cultured 
astrocytes. The studies of Saraf et al (36) 
in mice suggest that anti-amnesic activity 
may be partly due to restoration of NO 
release by reducing NOS inhibition. The 
protection from oxidative damage is 
achieved by maintaining functional 
integrity of mitochondria (55) and 
m e m b r a n e  i o n i c  b a l a n c e  ( 5 6 ) . 
Dhanasekeran et al (57) observed reduced 
concentration of divalent metals in 
addition to reduction in lipid peroxides 
and lipoxygenase activity. They suggest a 
role of the metals in reduction of β-
amyloid in brain of Alzheimer's disease 
animal models. 
 Kar Choudhury et al (58) have 
conducted studies in stressed rats. The 
decrease in Hsp expression and SOD 
70 
release was blocked. Similar results have 
been obtained by Annbarasi et al (59) in 
animals exposed to cigarette smoke. 
 Several neurotransmitters may be 
involved in nootropic activity of Bacopa 
preparations. An increase in 5-HT and 
lowering of norepinephrine has been 
found in hippocampus, hypothalamus and 
cerebral cortex of adult rats treated with 
bacosides without any effect on their 
receptors (1). Charles et al (60) treated 
young rats with Bacopa extract on post-
natal days 15-29. Their results suggest that 
nootropic activity may be mediated 
through regulation of expression of 
tryptophan hydroxylase (TPH ) leading to 
2
raised 5-HT level. Dopamine levels 
decreased signiﬁcantly but no changes 
were obtained in levels of glutamate or 
acetylcholine. Das et al (35), however, 
found inhibition of acetyl cholinesterase 
in mice brain and suggested involvement 
o f  a  c h o l i n e r g i c  m e c h a n i s m . 
Limpeanchob et al (33) also found a 
reduction of β-amyloid induced increase 
in acetyl cholinesterase activity in 
cultured cortical neurons with a Bacopa 
extract. Bacoside-A pre-treatment could 
revert fall  in GABA receptors in 
hippocampus of rat model of temporal 
epilepsy (61). The authors suggest 
possibility of modulation by a cholinergic 
mechanism 
 Kamkaew et al (62) studied the 
effect of alcoholic extract of Bacopa 
monniera on cerebra blood ﬂow in rats. 
There was 25% increase in cerebral blood 
ﬂow without any effect on systemic blood 
pressure. They suggest a role of improved 
blood supply in the nootropic effect.
 P r e e t h i  e t  a l  ( 6 3 )  h a v e 
demonstrated down-regulation of micro 
RNA-24 by Bacopa extract in young rats. 
It has been postulated that this would 
result in up-regulation of CREB which 
regulates activation of immediate early 
genes facilitating synaptic plasticity (64). 
p.CREB  is involved in regulation of 
1
synthesis of synaptic proteins necessary 
for consolidation of long term memory 
(65).  
Clinical Studies
 Normal Volunteers
 The ﬁrst Phase I study under GCP 
norms was undertaken at CDRI with 
standardized Bacoside preparation (CDRI 
B.N. Dhawan
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formulation) after generating the required 
pre-clinical efﬁcacy and safety (acute and 
chronic toxicity, teratogenicity and 
mutagenicity) data and obtaining 
approval from the Drugs' Controller 
General of India. The double blind 
placebo controlled study was conducted 
in male volunteers after obtaining 
informed consent. It was well tolerated 
and devoid of untoward effect in single 
(200-300mg) or multiple (100 and 200 mg 
daily for 4 weeks) dose schedules (1, 66). 
Pravina et al (67) found similar results in 
an open study in 23 volunteers given 
300mg daily for 15 days followed by 450 
mg for next 15 days.
 Nathan et al (68) studied effect of 
single 300 mg dose of CDRI formulation 
in a placebo controlled double blind study 
in 38 volunteers. It was found safe but had 
no effect on cognitive functioning. 
Administration of same dose for 3 months 
led to signiﬁcant improvement in 
information processing, learning and 
memory consolidation judged by storage 
and retention of new information (69, 70). 
 Mandal et al (71) gave 750 mg 
whole plant powder daily for 16 weeks in 
a placebo controlled double blind study. 
Signiﬁcant facilitation was observed in 
verbal span test, verbal memory task and 
text comprehension tests. Raina et al (72) 
compared the effect of 500 mg plant 
powder with 200 mg caffeine daily for 16 
weeks in 40 volunteers. Bacopa powder 
was better than caffeine in improving 
reaction time in a battery of cognitive tests 
with fewer side effects.
Senior Citizens with Memory Impairment   
 Most of the studies have been done 
with CDRI formulation.  Raghav et al (73) 
evaluated the effect of 12 weeks treatment 
in 40 subjects having Age-associated 
Memory Impairment without any 
evidence of dementia or psychiatric 
disorder. The study was double blind 
randomized. It signiﬁcantly improved 
mental control, logical memory and 
paired associated learning without any 
drug related abnormality in clinical, 
hematological or biochemical parameters.  
Signiﬁcant improvement in logical 
memory, digit forward, paired associated 
learning and total score was obtained in a 
study at another centre also (74). Similar 
results regarding efﬁcacy and safety has 
been obtained in several other placebo 
controlled double blind studies in India 
(75, 76) and abroad (77, 78).
 M o rg a n  a n d  S t e v e n s  ( 7 7 ) 
observed more gastrointestinal side 
effects than in the placebo treated group 
and suggest that these may be due to its 
cholinergic effects. Agrawal (79) has 
reported that treatment with Brahmi 
powder prevented depletion of blood 
a c e t y l c h o l i n e  i n  p a t i e n t s  o f 
psychosomatic disorders. 
Children with Impaired Learning
 A double blind placebo controlled 
s tudy has  been done wi th  CDRI 
formulation in 40 children with Attention 
Deﬁcit Memory Disorder (80). The drug 
or placebo was given for 12 weeks. 
Signiﬁcant improvement was observed in 
25
tests for mental control, sentence 
repetition, logical memory, word or 
picture recall and paired associated 
learning. Sharma et al (81) reported 
improvement in perpetual motor function 
in a placebo controlled trial in 40 school 
going children. Abhang (82) carried out a 
double blind study for one month in 100 
male students (10-13 years age) with 
subnormal IQ. There was improvement in 
direct memory, some verbal factors and 
arithmetic skill. 
Other CNS Disorders
 M u k h e r j e e  a n d  D a y  ( 8 3 ) 
published the ﬁrst clinical with Brahmi in 
1966. They compared the effect of 
defatted alcoholic extract (2-4 mg/kg) 
with aqueous extract (2 oz/day) for 5 
months in patients of epilepsy and found 
the former more effective. In a follow up 
study Dey (84) showed a close parallelism 
in clinical improvement and EEG changes 
in 2 of these patients
 Singh and Singh (85) treated 30 
cases of anxiety neurosis with 30 ml 
extract (prepared from 12g of crude drug) 
in two divided doses for one month. There 
was signiﬁcant relief in symptoms 
associated with a reduction in urinary 
excretion of vinyl mandellic acid and 
corticoids. Subsequently they gave dried 
extract of 2.5g crude drug in capsule thrice 
daily for 4 weeks to 18 normal subjects 
and same number of patients of anxiety 
neurosis (86). There was signiﬁcant 
improvement in symptoms of anxiety and 
depression, mental fatigue and memory 
span.
 Kumar et al (87) found signiﬁcant 
improvement in anxiety and stress level 
with the CDRI formulation given to 94 
adult volunteers for 6 months in a double 
blind placebo controlled cross-over study. 
Other recent studies have reported 
improvement in quantity and quality of 
sleep in post-menopausal women (88) and 
in the range of movement and joint pain 
etc. in patients of sciatica (89).
Concluding Remarks
 The CDRI formulation has been 
available as a prescription drug for 
memory disorders in India since 1994 
under several trade names. It has been 
subsequently being marketed as a 
prescription drug for same indications in 
Australia, New Zealand since 2009 and 
South Africa since 2011. It was made 
available as an OTC product in Sri Lanka 
in 1996 followed by Philippines (largest 
selling natural product), Malaysia (among 
top 5 selling herbal drugs), Singapore, 
Thailand and several African countries.
 Bacopa preparations show a wide 
spectrum of CNS effects in experimental 
studies. Initial clinical studies (reviewed 
above) indicate beneﬁcial effect in anxiety 
neurosis and epilepsy. This data along 
with animal and clinical safety data 
suggest the need of more extensive 
clinical trials in these and other relevant 
CNS disorders to assess its potential as 
primary treatment or adjunct to other 
drugs. They may also be useful in 
ameliorating detrimental effects of drugs 
like benzodiazepines or anticonvulsant 
drugs on cognitive function in patients 
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using these drugs for long periods. 
Experimental studies also suggest their 
potential utility in management of 
stressful conditions (90) and morphine 
abstinence syndrome (91).
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